Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
1.860
-0.040 (-2.11%)
Aug 17, 2026, 4:00 PM EDT - Market closed
Tvardi Therapeutics Employees
Tvardi Therapeutics had 12 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,171,917
Market Cap
17.45M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 12 | 0 | - |
| Dec 31, 2024 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Palatin Technologies | 29 |
| NeuroSense Therapeutics | 17 |
| Lipocine | 14 |
| Werewolf Therapeutics | 14 |
| NewcelX | 12 |
| KALA BIO | 6 |
| Marker Therapeutics | 5 |
TVRD News
- 1 day ago - Tvardi Therapeutics reports Q2 EPS (69c), consensus (63c) - TheFly
- 3 days ago - Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update - GlobeNewsWire
- 5 days ago - Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026 - GlobeNewsWire
- 18 days ago - Tvardi plans 2027 ulcerative colitis trial for oral STAT3 inhibitor TTI-109 - TheFly
- 18 days ago - Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109 - GlobeNewsWire
- 5 weeks ago - Tvardi Therapeutics upgraded to Overweight at Piper after Phase 1 data - TheFly
- 5 weeks ago - Tvardi Therapeutics upgraded to Overweight from Neutral at Piper Sandler - TheFly
- 5 weeks ago - Why Is Penny Stock Tvardi Therapeutics (TVRD) Up Today? - TipRanks